|
Total
|
BALF (+)
|
BALF (−)
|
P-value
|
OR (95% CI)a
|
---|
n = 285 (%)
|
n = 743 (%)
|
---|
Age (year)
| | | |
< 0.001
| |
≤ 25
|
244
|
105 (43.0)
|
139 (57.0)
| |
Reference
|
25–35
|
288
|
88 (30.6)
|
200 (69.4)
| |
0.582 (0.408–0.832)
|
35–45
|
215
|
44 (20.5)
|
171 (79.5)
| |
0.341 (0.224–0.517)
|
45–55
|
128
|
22 (17.2)
|
116 (82.8)
| |
0.251 (0.149–0.423)
|
55–65
|
106
|
23 (21.7)
|
83 (78.3)
| |
0.367 (0.217–0.621)
|
> 65
|
37
|
3 (8.1)
|
34 (91.9)
| |
0.117 (0.035–0.391)
|
Cavity
| | | |
< 0.001
| |
No
|
924
|
228 (24.7)
|
696 (75.3)
| |
Reference
|
Yes
|
104
|
57 (54.8)
|
47 (45.2)
| |
4.108 (2.376–7.102)
|
IGRA
| | | |
< 0.001
| |
Negative
|
431
|
64 (14.8)
|
367 (85.2)
| |
Reference
|
Positive
|
507
|
201 (39.6)
|
306 (60.4)
| |
3.743 (2.478–5.655)
|
CD8+
| | | |
0.002
| |
> 500
|
205
|
46 (22.5)
|
159 (77.5)
| |
Reference
|
≤ 500
|
468
|
153 (32.7)
|
315 (67.3)
| |
1.992 (1.289–3.076)
|
- TB tuberculosis, BALF bronchoalveolar lavage fluid, NAAT nucleic acid amplification test, IGRA interferon-γ release assays
- aControlling for variables with P < 0.05 in univariate analysis